drugset / Trial / NCT07248176
Universal CAR-T Cell Therapy for MM
Recruiting
6 enrolled
Bioray Laboratories
Shanghai Tongji Hospital, Tongji University School of Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
Timeline
- Start
- 2025-04-10
- Primary completion
- 2027-03-15
- Completion
- 2028-04-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection | Cell therapy | 5e+06 cells/kg | Intravenous |
| Subject | Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection | Cell therapy | 1e+07 cells/kg | Intravenous |